your comments about charging to collaborate moving forward is definitely something i believe we should be looking at.
To me management have been very clever with this in the past IMO to develop the pipeline without the extra costs. By completing a few collaborations jointly for Oncarlytics enabled IMU to have a proof of concept before jumping into a trail. I believe this is why they recently purchased the CarT arm of the business as they knew it worked and it gave them a product to progress trials without having to deal with other big pharmaceutical companies.
If our products work together in trials then the big boys will have to cough up heavily to use the oncarlytics platform with their CarT drugs.
your comments about charging to collaborate moving forward is...
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.2¢ |
Change
-0.003(3.53%) |
Mkt cap ! $600.2M | |||
| Open | High | Low | Value | Volume |
| 8.5¢ | 8.6¢ | 8.2¢ | $1.246M | 14.84M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 446526 | 8.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.3¢ | 535664 | 2 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
8.2¢ |
Change
-0.003 ( 2.38 %) |
||||
| Open | High | Low | Volume | ||
| 8.6¢ | 8.6¢ | 8.2¢ | 4518456 | ||
| Last updated 15.57pm 03/05/2024 ? | |||||
| IMU (ASX) Chart |